Synlogic (NASDAQ:SYBX) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Synlogic (NASDAQ:SYBX) in a report published on Monday, AnalystRatings.com reports. HC Wainwright currently has a $13.00 price target on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the company. Piper Jaffray Companies reaffirmed an overweight rating and set a $7.00 price target (down from $10.00) on shares of Synlogic in a research report on Wednesday, November 13th. Zacks Investment Research raised Synlogic from a hold rating to a buy rating and set a $2.75 price target on the stock in a research report on Thursday, January 9th. ValuEngine raised Synlogic from a hold rating to a buy rating in a research report on Friday, January 3rd. Finally, Chardan Capital reaffirmed a buy rating on shares of Synlogic in a research report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Synlogic currently has an average rating of Buy and an average price target of $13.72.

Shares of SYBX opened at $3.15 on Monday. The business’s 50-day moving average is $2.43 and its two-hundred day moving average is $3.56. The company has a market capitalization of $88.15 million, a P/E ratio of -1.55 and a beta of 2.61. The company has a debt-to-equity ratio of 0.14, a quick ratio of 12.70 and a current ratio of 12.70. Synlogic has a fifty-two week low of $1.91 and a fifty-two week high of $11.43.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.09. The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.46 million. Synlogic had a negative return on equity of 34.49% and a negative net margin of 4,574.82%. Analysts forecast that Synlogic will post -1.8 EPS for the current year.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Synlogic by 9.4% during the 2nd quarter. BlackRock Inc. now owns 1,317,063 shares of the biotechnology company’s stock worth $11,986,000 after acquiring an additional 113,665 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Synlogic by 0.3% during the 2nd quarter. Vanguard Group Inc. now owns 770,641 shares of the biotechnology company’s stock worth $7,013,000 after acquiring an additional 2,558 shares in the last quarter. State Street Corp boosted its stake in shares of Synlogic by 12.9% during the 3rd quarter. State Street Corp now owns 303,424 shares of the biotechnology company’s stock worth $695,000 after acquiring an additional 34,552 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Synlogic by 17.1% during the 2nd quarter. Northern Trust Corp now owns 201,613 shares of the biotechnology company’s stock worth $1,835,000 after acquiring an additional 29,401 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Synlogic by 11.1% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 37,208 shares of the biotechnology company’s stock worth $339,000 after acquiring an additional 3,708 shares in the last quarter. 61.00% of the stock is currently owned by institutional investors and hedge funds.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Further Reading: Treasury Bonds

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.